Submission of Un-Audited Financial Results for the Quarter ended on 31st December, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Skybiotech Healthcare Ltd (formerly Kapil Cotex Ltd) submitted its unaudited standalone and consolidated results for the quarter ended 31 December 2025. On a standalone basis, the company reported zero revenue and effectively no operations, with the old textile business appearing fully dormant. On a consolidated basis, revenue from operations for Q3 FY26 stood at Rs. 96.27 lakhs, sharply down from Rs. 191.65 lakhs in the previous quarter. The company posted a consolidated net loss of Rs. 48.47 lakhs for Q3 and Rs. 81.30 lakhs for the nine-month period, though this is an improvement from the Rs. 128.66 lakh loss in the comparable nine months of last year. The auditor SPD & Associates issued an unqualified limited review report with no qualifications or emphasis of matter. The company also noted its name change from Kapil Cotex to Skybiotech Healthcare, effective 7 November 2025, reflecting a strategic pivot to the healthcare/biotech segment through its subsidiary Skybiotech Lifesciences Pvt Ltd.
Persistent quarterly losses, declining sequential revenue, and a fully dormant standalone business are significant red flags for shareholders, though the narrower loss versus last year offers some comfort. The name change and shift of activity into the subsidiary suggest a strategic pivot that may take time to show results, making this a high-risk, turnaround-type situation.